Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial

Garway-Heath D.; Crabb D.; Bunce C.; Lascaratos G.; Amalfitano F.; Anand N.; Azuara-Blanco A.; Bourne R.; Broadway D.; Cunliffe I.; Diamond J.; Fraser S.; Ho T.; Martin K.; McNaught A.; Negi A.; Patel K.; Russell Richard A.; Shah Ameet; Spry P.; Suzuki Katsuyoshi; White E.; Wormald R.; Xing W.; Zeyen T.

doi:10.1016/s0140-6736(14)62111-5

← Today's brief

L2 StudySurrogate endpoint

Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial

Garway-Heath D. et al. · Lancet · Thursday, January 1, 2015

Read original

Design Level 2n 516Funding Not reported

The one catch: Surrogate endpoint, not a direct patient outcome.

Source

Garway-Heath D. et al.. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. Thursday, January 1, 2015.
doi:10.1016/s0140-6736(14)62111-5

Generated, then checked claim-by-claim against the source · how this brief was built →

Physician-designed methodology · Amr Saad, MD MBA

Sign in to rate and bookmark articles

Automated evidence summary, checked against the source. Not medical advice. Verify with the original publication.